SpringWorks Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
SpringWorks Therapeutics hat ein Gesamteigenkapital von $394.9M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $467.7M bzw. $72.8M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$479.20m |
Equity | US$626.22m |
Total liabilities | US$99.57m |
Total assets | US$725.79m |
Recent financial health updates
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30Recent updates
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15SpringWorks shows durable effect for neurofibroma therapy with long-term data
Jun 15SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma
Jun 07We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow
May 31SpringWorks Therapeutics EPS misses by $0.11
May 06SpringWorks Therapeutics announces C-level promotions
Dec 15SpringWorks Therapeutics EPS misses by $0.02
Nov 12Financial Position Analysis
Kurzfristige Verbindlichkeiten: SWTXDie kurzfristigen Aktiva des Unternehmens ($432.4M) übersteigen seine kurzfristigen Passiva ($50.3M).
Langfristige Verbindlichkeiten: SWTXDie kurzfristigen Vermögenswerte des Unternehmens ($432.4M) übersteigen seine langfristigen Verbindlichkeiten ($22.5M).
Debt to Equity History and Analysis
Verschuldungsgrad: SWTX ist schuldenfrei.
Schulden abbauen: SWTX hat in den letzten 5 Jahren keine Schulden gemacht.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stabile Start- und Landebahn für Bargeld: SWTX auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.
Vorhersage Cash Runway: SWTX verfügt über eine ausreichende Liquiditätsreserve für 1.8 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 43.6% pro Jahr abnimmt.